Mouse parvovirus infection potentiates rejection of tumor allografts and modulates T cell effector functions. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Mouse parvovirus infection potentiates rejection of tumor allografts and modulates T cell effector functions.

Transplantation. 1996 Jan 27;61(2):292-9. Unique Identifier : AIDSLINE MED/96166738
McKisic MD; Paturzo FX; Smith AL; Section of Comparative Medicine, Yale University School of; Medicine, New Haven, Connecticut 06520, USA.


Abstract: Lymphocytotropic mouse parvoviruses can perturb immune responses. For example the recently identified mouse parvovirus designated MPV-1 persistently infects lymphoid tissues and interferes with the ability of cloned T cells to proliferate. As a consequence of these findings the present studies were undertaken to characterize further the immunomodulatory effects of MPV-1 on T cell-mediated immune responses in vivo and in vitro. To evaluate the effect of MPV-1 on CD8+ T cell-mediated responses sarcoma I (SaI) cells, devoid of class II major histocompatibility (MHC) antigens, were administered to MPV-1-infected adult BALB/c mice. MPV-1 infection accelerated tumor allograft rejection. Immunofluorescence staining and in situ hybridization studies of tumors suggested that direct infection of the tumor cells was not responsible for accelerated rejection. Furthermore, compared with uninfected mice, T cells from infected mice that had rejected SaI tumors had a diminished cytolytic capacity. Taken together these results suggest that MPV-1 may induce bystander help. To examine the in vivo effect of MPV-1 on CD4+ T cell mediated responses adult mice were primed with ovalbumin (OVA) and infected with MPV-1. Spleen and popliteal lymph node cells from OVA-primed mice 3 or 7 days after MPV-1 inoculation had reduced proliferation responses, whereas the proliferative capacity of mesenteric lymph node cells from these mice was increased. Similarly, MPV-1 reduced cytokine-induced proliferation of allospecific CD8+ cloned L3 T cells and OVA-reactive CD4+ T cells without effecting cell viability. Since parvoviruses are widespread among laboratory rodents, these findings emphasize the importance of identifying and excluding parvovirus infections in mice used for transplantation studies and in cultures of mouse T lymphocytes.
Keywords: Animal CD4-Positive T-Lymphocytes/*IMMUNOLOGY CD8-Positive T-Lymphocytes/*IMMUNOLOGY Graft Rejection/*IMMUNOLOGY/VIROLOGY Lymphocyte Transformation Mice Mice, Inbred BALB C Mice, Inbred CBA Neoplasm Transplantation/*IMMUNOLOGY/PATHOLOGY Parvoviridae Infections/*IMMUNOLOGY Parvovirus/*IMMUNOLOGY Sarcoma, Experimental/IMMUNOLOGY/PATHOLOGY/VIROLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Transplantation, Homologous JOURNAL ARTICLEKWDanimalcd4-positivet-lymphocytes/KWDimmunologycd8-positivet-lymphocytes/KWDimmunologygraftrejection/KWDimmunology/virologylymphocytetransformationmicemice,inbredbalbcmice,inbredcbaneoplasmtransplantation/KWDimmunology/pathologyparvoviridaeinfections/KWDimmunologyparvovirus/KWDimmunologysarcoma,experimental/immunology/pathology/virologysupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,pKWDhKWDsKWDtransplantation,homologousjournalarticle
960730
M9670488

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .